This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accelrys' Electronic Laboratory Notebooks Recognized In Gartner's Enterprise Category

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ --  Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that Gartner, Inc­., the leading provider of research and analysis on the global information technology industry, has rated the company's electronic laboratory notebooks (ELN) as "very high" or "high" in each scientific and functional domain in a recent report on considerations for selecting an ELN. Accelrys was the only vendor with ELNs that achieved those ratings in all categories.


The report, published Jan. 11, 2013 and titled "Manufacturers Must Consider Scientific Domain Expertise During ELN Selection," is based on insights collected by Gartner throughout hundreds of interviews, briefings and interactions with various clients. The Accelrys ELN secured a "very high" rating in chemistry, meaning the product is close to becoming a de facto standard in that category, as well as "high" ratings in biology, formulation, engineering, regulated environments and translational medicine. The Accelrys Laboratory Execution System was rated  "very high" in regulated environments and "high" in formulation, while the Contur ELN rated "high" in chemistry.

"In the push to reduce innovation cycle times and share information among scientists and engineers, ELN technologies have the potential to be valuable tools, especially for transferring knowledge from ideas into product development," Gartner research director Michael Shanler said in the report. "However, as companies move toward "end-to-end" informatics solutions that extend from research into manufacturing, deep scientific functionality is often compromised when moving toward single solution providers. While IT often weights value for lower cost, simple governance and architecture simplicity, R&D sees deep scientific functionality as the primary criterion for sustaining innovation."

"With deep scientific domain experience and an integrated set of solutions for optimizing the lab-to-commercialization value chain – from research through downstream analytical development, quality control, quality assurance and manufacturing – Accelrys is proving that neither functionality nor expertise should be compromised in the quest to improve innovation," said Accelrys President and CEO Max Carnecchia. "We believe Gartner's 'high' and 'very high' ratings of our ELNs confirm our industry leading position in the market and our ability to deliver a breadth of solutions across scientific and functional domains for a diverse and global customer base."

About Accelrys, Inc.Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit

SOURCE Accelrys, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.72 -0.56%
FB $119.49 1.43%
GOOG $711.12 1.38%
TSLA $214.93 1.61%
YHOO $37.23 0.79%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs